Open dataset · CC BY 4.0
Side-effect discussion intensity by compound
Counts and shares of side-effect-classified discussion per peptide compound, with the mean sentiment of those posts, computed over public Reddit and X discussion classified by MyPeptideStory. Aggregate counts only. Compounds with fewer than five posts overall are suppressed; side-effect counts below the same threshold are reported as 'fewer than 5'.
How to read this
This is NOT pharmacovigilance data and must not be used as such. It counts posts our classifier placed in a side-effect category; it does not identify individual cases, does not establish causality, and is not structured for adverse-event reporting. Anyone with a regulatory reporting obligation should treat this as a discussion metric only.
Aggregate counts only. No post text, author identifiers or permalinks are published here or in the CSV. Any group with fewer than 5 underlying posts is suppressed rather than reported, which is both a privacy control and a statistical one — a share derived from four posts is noise.
| Compound | Posts | Side-effect posts | Side-effect % | Mean sentiment |
|---|---|---|---|---|
| GHK-Cu | 341 | 29 | 8.5 | 0.116 |
| DSIP | 74 | 6 | 8.1 | 0.415 |
| Semaglutide | 573 | 46 | 8 | -0.304 |
| Tirzepatide | 1672 | 129 | 7.7 | -0.167 |
| Tesamorelin | 200 | 14 | 7 | -0.095 |
| MOTS-c | 342 | 23 | 6.7 | 0.038 |
| CJC-1295 / Ipamorelin | 180 | 12 | 6.7 | -0.177 |
| Selank | 156 | 10 | 6.4 | 0.55 |
| Cerebrolysin | 101 | 6 | 5.9 | 0.288 |
| KPV | 262 | 12 | 4.6 | 0.181 |
| TB-500 | 155 | 7 | 4.5 | 0.02 |
| Retatrutide | 516 | 20 | 3.9 | -0.227 |
| Semax | 211 | 8 | 3.8 | 0.513 |
| Epitalon | 148 | 5 | 3.4 | 0.1 |
| BPC-157 | 506 | 14 | 2.8 | 0.096 |
| Kisspeptin | 24 | fewer than 5 | 0 | 0 |
| Melanotan-II | 64 | fewer than 5 | 0 | 0 |
| Orforglipron | 25 | fewer than 5 | 0 | 0 |
| Dihexa | 41 | fewer than 5 | 0 | 0 |
| Oxytocin | 42 | fewer than 5 | 0 | 0 |
| Larazotide | 5 | fewer than 5 | 0 | 0 |
| MK-677 (Ibutamoren) | 9 | fewer than 5 | 0 | 0 |
| PT-141 | 20 | fewer than 5 | 0 | 0 |
| Sermorelin | 39 | fewer than 5 | 0 | 0 |
| 5-Amino-1MQ | 31 | fewer than 5 | 0 | 0 |
| AOD-9604 | 12 | fewer than 5 | 0 | 0 |
| FOXO4-DRI | 5 | fewer than 5 | 0 | 0 |
| CagriSema | 12 | fewer than 5 | 0 | 0 |
| SNAP-8 | 5 | fewer than 5 | 0 | 0 |
Licence and citation
Published under CC BY 4.0. Use it, including commercially, with attribution.
MyPeptideStory. Side-effect discussion intensity by compound. 2026. https://www.mypeptidestory.com/data/peptide-side-effect-discussion
Richer cuts — outcome verdicts, discontinuation reasons, supply-channel splits and time series — are part of Peptide Signal.